[Intravenous inmunoglobulins in pediatrics].
The use of intravenous immunoglobulins remains controversial after their introduction in therapeutics during the 80s. Their mechanism of action remains unexplained for certain pathologies, but their application to new indications and their economical impact makes them a target of many studies and protocols of use. Intravenous immunoglobulins are administred as substitution therapy in primary and secondary immunodeficiencies. On the other hand, their immunomodulating effect is the basis of their use on a great variety of autoimmune diseases and inflammatory processes, although not always following the authorised indications. This study reviews the use of intravenous immunoglobulins in pediatric population, making the distinction between the indications authorised by the regulatory authorities, and those non-authorised but supported by scientific publications.
Panadero Esteban
M I
MI
Servicio de Farmacia, Hospital Montepríncipe, Hospital Universitario Miguel Servet. Zaragoza. Spain.
Carcelén Andrés
J
J
Urbieta Sanz
E
E
Viñuales Armengol
M C
MC
Idoipe Tomás
A
A
D001327:Autoimmune Diseases / Q000188:drug therapy; D002648:Child; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy
D016756:Immunoglobulins, Intravenous